Jane Street Group LLC Purchases 24,945 Shares of Artivion, Inc. (NYSE:AORT)

Jane Street Group LLC increased its holdings in Artivion, Inc. (NYSE:AORT) by 69.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,035 shares of the company’s stock after acquiring an additional 24,945 shares during the quarter. Jane Street Group LLC owned approximately 0.15% of Artivion worth $1,625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AORT. nVerses Capital LLC purchased a new position in shares of Artivion in the 2nd quarter valued at $28,000. Quarry LP lifted its position in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the last quarter. RiverPark Advisors LLC boosted its holdings in shares of Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after buying an additional 3,246 shares in the last quarter. RW Investment Management LLC purchased a new position in shares of Artivion in the 2nd quarter worth approximately $219,000. Finally, Intech Investment Management LLC bought a new position in shares of Artivion during the 2nd quarter worth approximately $253,000. 86.37% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. The trade was a 8.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the sale, the vice president now directly owns 33,503 shares in the company, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,447 shares of company stock valued at $925,424 in the last ninety days. Insiders own 8.10% of the company’s stock.

Artivion Trading Up 2.8 %

Artivion stock opened at $29.34 on Friday. Artivion, Inc. has a 52 week low of $16.48 and a 52 week high of $30.45. The stock has a 50-day moving average price of $28.09 and a 200 day moving average price of $26.49. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -1,467.00 and a beta of 1.75.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Oppenheimer raised their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Artivion in a research report on Monday, December 9th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus increased their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.80.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.